Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Qiagen N.V. Common Shares (NY:QGEN)

39.97 -0.13 (-0.32%)
Official Closing Price Updated: 6:30 PM EDT, Apr 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2021 ↗
Upgrades CL King upgraded the previous rating for Compass Minerals International Inc (NYSE: 
Via Benzinga
News headline image
Qiagen Stock Drops After Trimming FY21 Earnings Forecast On Weaker COVID-19 Testing Trends ↗
Qiagen NV (NYSE: QGEN) has reported higher-than-expected second-quarter interim earnings but lowered its outlook on weaker demand for COVID-19 tests, sending its... 
Via Benzinga
News headline image
QIAGEN N.V. Conference Call on July 13 to Discuss Preliminary Q2 2021 Results
From QIAGEN N.V.
Via Business Wire
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
News headline image
Earnings Scheduled For July 29, 2021 ↗
Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter. • Cohen & Co (AMEX:COHN) is... 
Via Benzinga
News headline image
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
News headline image
QIAGEN announces preliminary Q2 2021 results exceeding outlook, updates full-year 2021 outlook for declining COVID-19 test trends and plans new $100 million share repurchase program
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN’s NeuMoDx™ HAdV Quant Assay Secures CE-IVD Certification for Automated Testing to Detect Human Adenovirus Infections
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN launches the Workflow Configurator to help life science researchers simplify and optimize their laboratory experiments
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Forms Strategic Alliance With Sysmex Corporation for Global Cancer Companion Diagnostics Development and Commercialization Using NGS and Plasma-Safe-SeqS Technology
From QIAGEN N.V.
Via Business Wire
News headline image
Verogen Partners with QIAGEN to Deliver Innovative Solutions for Human Identification Laboratories
From Verogen
Via Business Wire
News headline image
QIAGEN Partners with Verogen to Offer Broadest Portfolio for Human Identification, Including Next Generation Sequencing Solutions
From QIAGEN N.V.
Via Business Wire
News headline image
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 21) Agios Pharmaceuticals, Inc... 
Via Benzinga
News headline image
Qiagen Launches CRISPR-Specific Products For Gene-Editing Experiments ↗
Qiagen NV (NYSE: QGEN) has launched dedicated solutions specific to CRISPR technology used for editing genomes and modifying gene function. QiaPrep&Amp CRISPR... 
Via Benzinga
News headline image
QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments
From QIAGEN N.V.
Via Business Wire
News headline image
5 Top ETFs With Exposure To Biogen ↗
For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021 ↗
Upgrades According to B of A Securities, the prior rating for Bloom Energy Corp (NYSE:BE) was changed from Underperform to Neutral. For the first quarter, Bloom Energy had... 
Via Benzinga
News headline image
Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer ↗
The FDA has given accelerated approval to Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) for non-small cell lung cancer (NSCLC) patients harboring kras... 
Via Benzinga
News headline image
QIAGEN Launches First FDA-approved Tissue Companion Diagnostic to Identify the KRAS G12C Mutation in NSCLC Tumours and Expand Precision Medicine Options in Lung Cancer
From QIAGEN N.V.
Via Business Wire
News headline image
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
News headline image
QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC)
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Announces Creation of Scientific Advisory Board and Agenda for Annual General Meeting in June 2021
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Receives U.S. FDA Emergency Use Authorization for Fast and Easy-to-Use Digital Test to Detect SARS-CoV-2 Coronavirus Antibodies
From QIAGEN N.V.
Via Business Wire
News headline image
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc... 
Via Benzinga
News headline image
Qiagen NV (QGEN) Q1 2021 Earnings Call Transcript ↗
QGEN earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Qiagen Q1 Earnings Tops Estimates As Growth In Non-COVID-19 Products Boost Revenues ↗
Qiagen NV (NYSE: QGEN) on Monday after-hours reported first-quarter revenue growth of 52% Y/Y to $567.2 million, exceeding prior guidance and beating analyst... 
Via Benzinga
News headline image
Recap: Qiagen Q1 Earnings ↗
Shares of Qiagen (NYSE:QGEN) quite in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 94.12% year over year to $0.66... 
Via Benzinga
News headline image
QIAGEN Exceeds Outlook in First Quarter 2021 Results, Reaffirms Sales Growth and Profitability Outlook for Full-Year 2021
From QIAGEN N.V.
Via Business Wire
News headline image
Qiagen's Earnings: A Preview ↗
On Monday, May 03, Qiagen (NYSE:QGEN) will release its latest earnings report. Decipher the announcement with Benzinga's help. Net Income, Earnings, And Earnings Per Share... 
Via Benzinga
News headline image
Earnings Scheduled For May 3, 2021 ↗
Companies Reporting Before The Bell • Scienjoy Holding (NASDAQ:SJ) is estimated to report quarterly earnings at $0.58 per share on revenue of $540.11 million. •... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.